Loading
A phase 3 trial of 18F-MFBG in neuroblastoma, run by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), now completed.
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma is a phase 3 interventional study registered as NCT04724369 by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), with 43 participants enrolled, started 2021-11-18 and reached its primary completion in 2026-07-30. Interventions recorded: 18F-MFBG.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/